ScholarIQanswers from OpenAlex
European School of Molecular Medicine
InstitutionResearch output, impact & collaborations
European School of Molecular Medicine is a institution indexed in ScholarIQ from OpenAlex.
What is known about European School of Molecular Medicine?
ScholarIQrecord summary
European School of Molecular Medicine is a research organisation in Milan, IT. OpenAlex records 779 works and 67,486 citations for it. 159 researchers list it as their most recent affiliation.
How many works does European School of Molecular Medicine have?
ScholarIQindexed works
European School of Molecular Medicine has 779 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does European School of Molecular Medicine have?
ScholarIQcitation count
European School of Molecular Medicine has 67,486 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at European School of Molecular Medicine?
ScholarIQresearcher count
European School of Molecular Medicine has 159 researchers in the ScholarIQ index.
What is the average h-index at European School of Molecular Medicine?
ScholarIQavg h-index
European School of Molecular Medicine has an average h-index of 85.5 in OpenAlex.
What is the ROR of European School of Molecular Medicine?
ScholarIQror
The ROR for European School of Molecular Medicine is on the source record.
What is the OpenAlex record for European School of Molecular Medicine?
ScholarIQopenalex
The OpenAlex for European School of Molecular Medicine is on the source record.
Who are the most-cited researchers behind European School of Molecular Medicine?
ScholarIQtop researchers by citations
What are the most-cited papers on European School of Molecular Medicine?
ScholarIQmost cited works
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T. Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent‐Puig, Frédérique Penault–Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric FIORE, Alice Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M. Comoglio, Alberto Bardelli, Silvia Marsoni, Salvatore Siena
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, María Gomez‐Caraballo, Faria M. Siddiqui, Hillary E. Mulvey, Yosef E. Maruvka, Fei Ji, Hyo-Eun Carrie Bhang, Viveksagar Krishnamurthy Radhakrishna, Giulia Siravegna, Haichuan Hu, Sana Raoof, Elizabeth L. Lockerman, Anuj Kalsy, Dana Lee, Celina L Keating, David A. Ruddy, Leah J. Damon, Adam Crystal, Carlotta Costa, Zofia Piotrowska, Alberto Bardelli, A. John Iafrate, Ruslan I. Sadreyev, Frank Stegmeier, Gad Getz, Lecia V. Sequist, Anthony C. Faber, Jeffrey A. Engelman
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun, Liqin Wang, Sidong Huang, Guus J.J.E. Heynen, Anirudh Prahallad, Caroline Robert, John B.A.G. Haanen, Christian U. Blank, Jelle Wesseling, Stefan M. Willems, Davide Zecchin, Sebastijan Hobor, Prashanth Kumar Bajpe, Cor Lieftink, Christina Mateus, Stéphan Vagner, Wipawadee Grernrum, Ingrid Hofland, Andreas Schlicker, Lodewyk F.A. Wessels, Roderick L. Beijersbergen, Alberto Bardelli, Federica Di Nicolantonio, Alexander M.M. Eggermont, René Bernards
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore‐Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata‐Ford, John Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar
How much of the research on European School of Molecular Medicine is open access?
ScholarIQopen access share
67%OPEN ACCESS